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Background/aim: Congenital hypothyroidism (CH) is divided into two groups as ‘permanent’ and ‘transient’. We aimed to determine
the rate of transient and permanent congenital hypothyroidism of the newborns referred to our clinic.
Materials and methods: Of the newborns who were referred to our clinic from the neonatal screening program, those who were
diagnosed with CH and started treatment were included in the study. The treatments of the patients whose required daily treatment dose
was reduced to under 1 µg/kg were terminated and those who were followed monthly and whose fT4 and thyroid-stimulating hormone
(TSH) levels were normal at least 3 times without treatment were considered to have transient hypothyroidism.
Results: Of the 256 newborns referred to our clinic from the neonatal screening program, 114 (44.5%) were diagnosed with CH. Of the
CH patients, 70% (n = 58) were evaluated to have permanent and 30% (n = 25) transient hypothyroidism. Neonatal and serum TSH
levels and treatment doses were found to be significantly lower in the transient hypothyroidism patients.
Conclusion: Initial measurements of the serum TSH level and the required doses of L-thyroxine therapy for maintaining normal thyroid
hormone levels, growth, and development may have a predictive role for differentiating permanent forms of CH from transient forms.
Key words: Thyroid, congenital hypothyroidism, transient, permanent

1. Introduction
Congenital hypothyroidism (CH) is a disease where
screening is essential as the disorder is the most common
cause of preventable mental retardation; neurological
problems can be prevented with early diagnosis and
treatment; treatment is inexpensive, easy, and effective;
and there is no disease-specific clinical finding in more
than 95% of the sick babies in the neonatal period. CH
was included in the neonatal screening program in Turkey
approximately 7 years ago. Although multiple methods
are in use globally, the most common one, as in Turkey,
is thyroid-stimulating hormone (TSH) measurement from
a blood sample taken from the heel in the first week of
life (between days 3 and 7). Congenital hypothyroidism
is divided into two main groups as ‘permanent’ and
‘transient’. The deficiency of thyroid hormone production
in permanent CH continues throughout life and requires
continuous treatment. Approximately 85% of permanent
CH cases are sporadic (the most common reason is
thyroid dysgenesis) and 15% are hereditary (mostly
congenital disorders of thyroid hormone synthesis). A
transient deficiency is detected in the thyroid hormones
* Correspondence: drhnpeltek@yahoo.com

at birth in transient CH, but typically normal thyroid
hormone production occurs in the first months or years of
life. Maternal and/or neonatal iodine deficiency or iodine
overload, maternal antithyroid drug use in pregnancy,
transplacental passage of TSH receptor blocker antibodies,
congenital hepatic hemangioma/hemangioendothelioma,
and heterozygous mutations in the THOX2 or DUOXA2
genes can cause transient CH (1). Diagnosis of transient
hypothyroidism is important to avoid lifelong unnecessary
therapy with its possible side effects. The financial burden
for this unnecessary therapy could also be invested in
other health care services (2).
We aimed to determine the rate of transient and
permanent CH of the newborns referred to our clinic with
a preliminary diagnosis of CH from the neonatal screening
program in this study.
2. Materials and methods
Children diagnosed with congenital hypothyroidism who
started treatment among the newborn babies who were
referred to the Dr. Sami Ulus Women and Children’s Health
Training and Research Hospital Pediatric Endocrinology
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Clinic between May 2009 and August 2011 from the
neonatal screening program due to TSH elevation were
included in the study. The data of the patients recorded
in the hospital’s information administration system were
retrospectively analyzed.
TSH measurement in capillary whole blood taken
after postnatal day 3 is used for neonatal hypothyroidism
screening in Turkey. The TSH cut-off level was 15 mIU/L
between May 2009 and August 2011. Babies with a
capillary blood TSH level between 15 and 50 mIU/L were
recalled for repeat TSH measurement and the serum TSH
and free T4 (fT4) levels of the babies whose TSH level in the
repeated sample was over 15 mIU/L or whose TSH level in
the first capillary blood sample was over 50 mIU/L were
measured. Of the babies found to have serum fT4 decrease
or TSH elevation and referred to our clinic, patients with a
TSH level over 10 mIU/L and fT4 level at the lower normal
limit or below were diagnosed with ‘primary CH’ and were
started to be treated with L-thyroxine at a daily dose of
8–15 µg/kg by taking their fT4 levels into account. The
L-thyroxine dose may be increased or decreased based on
the normalization of the T4/TSH levels. Infant diagnosed
with CH were followed every month for the first year and
every 2–3 months thereafter. The birth weight, time of birth
(prematurity status), neonatal screening day, application
date, neonatal TSH, serum TSH, total T4 (TT4), fT4 levels,
treatment initiation age, follow-up period, transient
hypothyroidism treatment stoppage time, drug dose at
time of discontinuation, and duration of follow-up after
treatment discontinuation of the patients diagnosed with
CH were evaluated. Sonographic evaluation of the thyroid
gland (thyroid USG) was performed and the etiology was
evaluated. The transverse (T), anteroposterior (AP), and
sagittal (S) lengths of the thyroid gland lobes were measured
and each lobe volume was calculated separately (T × AP ×
S × pi/6). The lobe volumes were added without including
the isthmus to find the thyroid volume. The thyroid was
considered to have normal volume when the volume was
between 0.44 and 1.5 mL, hypoplastic when ≤0.44 mL,
and hyperplastic when ≥1.5 mL (3). Excluding those who
were known to have permanent hypothyroidism, patients
with a normal clinical and laboratory course whose daily
required treatment dose fell under 1 µg/kg and whose
treatment was terminated, who continued monthly followup, and whose fT4 and TSH levels were normal at least 3
times without treatment were considered to have ‘transient
hypothyroidism’. The clinical and laboratory findings of
the transient and permanent hypothyroidism patients at
admission and during follow-up were compared.
Thyroid function tests were performed at the
biochemistry laboratory of our hospital by using the
immune chemiluminescence method with an Advia
Centaur device. The normal range was 0.8–5.4 µIU/mL for
TSH and 0.9–2.1 ng/dL for fT4 (4).
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2.1. Statistical analyses
SPSS 16.0 was used for statistical analyses. The
Kolmogorov–Smirnov test was used to determine normal
distribution. Descriptive statistics were presented as
mean ± standard deviation (SD) for normally distributed
data and as counts and percentages for categorical data.
The relationship between the categorical variables was
examined using the chi-square test. Student’s t-test was
used for the comparison of two groups with normally
distributed variables, and the Mann–Whitney U test
was used for data not normally distributed. Results were
evaluated with a confidence interval of 95%, and P < 0.05
was considered statistically significant.
3. Results
We diagnosed CH in 114 of 256 newborns who were
referred to our clinic from neonatal screening programs
(44.5%) (Table 1). Of these patients, 58.7% (n = 67) came
from Afyonkarahisar, 22.8% (n = 26) from Ankara, and
18.5% (n = 21) from provinces neighboring Ankara.
The mean birth weight of patients with CH was 3230
± 486 g (2140–4500). Three of these patients (2.6%) had
a history of premature birth and 3 patients (2.6%) had a
history of maternal antithyroid drug use. Girls made up
55.3% of the patients (n = 63). The mean thyroid volume
of the 105 patients whose thyroid imaging was performed
was 0.86 ± 0.49 (0.17–2.2) mL with 13.3% (n = 14) of the
patients found to have hypoplasia, 6.6% (n = 7) agenesis,
1.9% (n = 2) ectopia, and 10.4% (n = 11) hyperplasia.
A normal thyroid was present on USG in 67.6% of the
patients (n = 71).
Of the patients who were followed with a diagnosis
of CH, 27.2% (n = 31) did not attend regular follow-up
appointments. Therefore, evaluations were performed in
the 83 cases that could be followed. Of the CH patients,
70% (n = 58) were evaluated as having permanent and
30% (n = 25) as having transient hypothyroidism. The
patients with CH were treated for 18.1 ± 11.5 (2.0–43.0)
months and were followed for an additional 14.8 ± 8.0
(3.0–36) months after the termination of their treatments.
One patient whose treatment was terminated had to start
treatment again.
The male/female ratio was 1.08 in patients with
transient hypothyroidism and 1.5 in those with
permanent hypothyroidism. No statistical difference was
found between the groups in terms of sex distribution
(P = 0.322). There was no difference between the birth
weight, days of screening and application, serum fT4 and
TT4 levels, thyroid volume, and treatment start time in
comparison of the findings of patients with permanent
and transient hypothyroidism, whereas the neonatal and
serum TSH levels in the transient hypothyroidism group
were significantly lower. L-thyroxine doses were found to
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Table 1. The characteristics of hypothyroidism patients at admission.
Mean ± SD

Min–max

Birth weight (g)

3230 ± 486

2140–4500

Day of application

21.3 ± 10.2

4.0–75.0

Day of screening

8.44 ± 5.93

1.0–25.0

Neonatal TSH (µIU/mL)

48.1 ± 28.3

15.1–111.8

Serum TSH (µIU/mL)

55.2 ± 33.85

10.7–150.0

Serum TT4 (µg/dL)

6.42 ± 2.98

1.00–13.4

Serum fT4 (ng/dL)

0.82 ± 0.42

0.3–2.1

Thyroid volume (mm3)

0.86 ± 0.49

0.17–2.2

Time of the treatment initiation (day)

19.7 ± 8.30

5–60

Treatment duration (months)

24.7 ± 12.9

2–50

Treatment dose (µg kg–1 day–1)

2.29 ± 1.33

0.9–8.25

Follow-up duration (months)

27.7 ± 12.9

3–51

be significantly higher in the permanent CH group (Table
2). All the patients with a history of maternal antithyroid
drug use were found to have transient CH. A history of
premature birth was present in 3.4% (n = 2) of the patients
with permanent CH and 4% (n = 1) of the patients with
transient CH.
4. Discussion
We found that 44.5% of newborns were found to have
TSH elevation in the neonatal screening program and
were referred to our clinic with CH. Among the CH group,
30% had transient CH in this study. Excluding those who
were known to have permanent hypothyroidism, patients
with a normal clinical and laboratory course whose daily
required treatment dose fell under 1 µg/kg and whose
treatment was terminated, and the patients on monthly
follow-up whose fT4 and TSH levels were normal at
least 3 times without treatment, were considered to have
transient hypothyroidism in our study. The definition
of transient hypothyroidism in the medical literature is
variable. Different descriptions are used even in different
parts of the same country. There are therefore likely to be
significant differences between the reported incidence rates
of transient hypothyroidism depending on its definition
(2). Treatment of children with CH, excluding those
known to have thyroid dysgenesis, is usually terminated
around the age of 3 in the literature and those who do not
require drug treatment afterwards are considered to have
experienced transient CH. Studies from other parts of the
world that use this description have reported the incidence
of transient hypothyroidism in children with CH as 1%–

50%. It is generally accepted that 10–15% of primary CH
patients are diagnosed with the transient type (5). The
transient CH rate was 38% in France (6) and 38.1% in Italy
(7). The same rate was 46.4% and 40.2% in two different
studies conducted in Iran (8,9). In addition to these rates
that are higher than those in our study, lower transient CH
rates such as 17.7% in Egypt (5) and 8.3% in Saudi Arabia
(10) have also been reported. The transient CH rate in the
United States has been reported as 28%, similar to our
results (11,12). These variations in incidence may be due
to different environmental, genetic, and immunological
factors as well as ethnicity. A study from İstanbul studied
182 patients and found 54 (35.7%) patients with transient
hypothyroidism, 97 (64.3%) with permanent CH, and 31
patients with isolated hyperthyrotropinemia (13). The
transient CH rate was 23.7% in a study conducted in İzmir
(14). Of the patients in our study, 58.7% (n = 67) came
from Afyonkarahisar in the Aegean region where the
studies of Ünüvar et al. were conducted (14), but the rest
were from Ankara and neighboring provinces. The reason
for the difference in the rate of transient CH may be due to
the environment where the patients lived.
The different etiology of transient CH between regions
may also cause differences in incidence. Transient CH
may be due to maternal factors such as iodine deficiency,
excessive iodine intake, antithyroid medication, or
presence of antibodies against thyroid tissue during
pregnancy. Very low birth weight (<1500 g), prematurity
(<37 weeks gestation), immaturity of thyroidal iodine
organification, exposure to excess iodine (e.g., use of
iodinated disinfectants or contrast agents), and gene
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Table 2. The characteristics of patient groups with transient and permanent hypothyroidism, mean ± SD (min–max).
Characteristics

Permanent hypothyroidism (n = 58)

Transient hypothyroidism (n = 25)

P

Birth weight (g)

3233.9 ± 448.7 (2140–4500)

3223.9 ± 574.1 (2390–4500)

0.935

Day of application

19.2 ± 9.1 (6.0–64.0)

21.5 ± 9.08 (4.0–43.0)

0.828

Day of screening

6.7 ± 5.7 (1.0–22.0)

9.8 ± 5.6 (1.0–21.0)

0.762

Neonatal TSH (µIU/mL)

52.4 ± 31.2 (15.1–111.8)

38.4 ± 20.5 (15.2–98.0)

0.002

Serum TSH (µIU/mL)

60.7 ± 37.1 (10.7–150)

42.5 ± 18.3 (19.7–75)

0.002

Serum TT4 (µg/dL)

6.2 ± 2.9 (1.0– 12.7)

7.3 ± 2.7 (2.0–12.3)

0.464

Serum fT4 (ng/dL)

0.7 ± 0.3 (0.3–2.2)

0.7 ± 0.2 (0.3–1.3)

0.139

Thyroid volume (mm3)

0.8 ± 0.5 (0.1–2.2)

0.9 ± 0.4 (0.5–1.2)

0.558

Time of the treatment initiation (day)

18.9 ± 7.7 (6.0–47.0)

21.8 ± 8.0 (10.0–43.0)

0.860

Treatment duration (months)

29.2 ± 11.0 (3.0–50.0)

18.1 ± 11.5 (2.0–43.0)

0.842

Treatment dose (µg kg–1 day–1)*

2.2 ± 1.3 (0.9–8.2)

0.6 ± 0.3 (0.6–0.9)

0.004

Follow up duration (months)

29.5 ± 11.1 (3.0–51.0)

32.5 ± 11.1 (12–50)

0.921

*This is the dose at final follow-up for patients with permanent hypothyroidism and the dose at discontinuation of treatment in patients
with transient hypothyroidism.

mutation may also contribute to transient CH. The reason
for the hypothyroidism cannot be determined in some
cases (9,15–17). A history of maternal antithyroid drug
use was present in 2.6% (n = 3) of our patients and all were
diagnosed to have transient CH. A history of premature
birth was present in 3.4% of the patients with permanent
CH (n = 2) and 4% of the patients with transient CH (n =
1). On a global basis, iodine deficiency is the most common
cause of transient hypothyroidism (5). Although the use
of iodized salt has become mandatory in Turkey since the
initiation of the national program in 1998, studies have
shown that the rate of iodine deficiency continues to be
significantly high in sensitive populations such as pregnant
women and nursing mothers (18). In addition, iodine
deficiency has also been found at a rate of 41.9% in school
children (19). The maternal and neonatal iodine statuses
and whether antibodies against thyroid tissue were present
were not known in our study. These are limitations of our
study.
The reported female-to-male sex ratio among infants
with true CH was 2:1 in studies of European, Australian,
and Canadian newborns. The ratio was even higher
(2.4:1.0) among newborns with CH caused specifically by
thyroid aplasia or ectopia (2). Studies in Italy reported the
female-to-male ratio as 2:1 among newborns with thyroid
dysgenesis, which accounted for 75% of all newborns with
CH; 1:1 among newborns with CH with eutopic (normally
positioned and normal appearing) glands; and 0.5:1.0
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among newborns with transient hypothyroidism (20). In
a Scottish study, the female to male sex ratio was 2.2:1.0
among 224 newborns with definite CH and 1:1 among 88
newborns with transient hypothyroidism (21). Although
we found no statistical difference between patients with
transient and permanent CH in terms of sex distribution,
the male/female ratio was 1.08 in patients with transient
CH and 1.5 in those with permanent CH. Although our
rates are not as high as in other studies, we similarly
found an increased percentage of female patients in the
permanent CH group.
The median neonatal and serum TSH levels before
treatment were significantly higher in patients with
permanent CH than those with transient CH in our study.
Similar findings were reported from Iran by Hashemipour
et al. (9) and from India by Nair et al. (22). The median
TT4 and fT4 levels before starting treatment were not
significantly different among patients with permanent and
transient CH. This was reported also by Hashemipour et
al., while the initial T4 levels correlated with the etiology
of CH in other reports (23). These findings indicate that
the first TSH and T4 levels may have a predictive role
for differentiating the permanent forms of CH from the
transient forms.
The most common cause of permanent CH is
thyroid dysgenesis (1). On the other hand, Gaudino et
al. (6) and Lombard et al. (24) reported the frequency
of dyshormonogenesis to be higher than that of thyroid
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dysgenesis among patients with CH. Thyroid dysgenesis
was the cause of permanent CH in 21% of the cases in our
study. We think that this difference between the results is
associated with the higher frequency of consanguineous
marriage in our region, the small patient population, and
the presence of undiagnosed CH in the family history.
Several studies in the literature reported permanent
CH patients to require higher doses of L-thyroxine for
TSH and fT4 normalization. Similarly, other studies have
shown that low-dose L-thyroxine therapy was sufficient
for maintaining normal thyroid hormone levels, growth,
and development in patients with transient CH (14). The
L-thyroxine dose requirement in the permanent CH group
was higher than in the transient CH group in our study

and this was consistent with the literature.
In conclusion, the high incidence of transient CH in
our study could be explained by iodine deficiency. Initial
measurements of serum TSH level and the required doses
of L-thyroxine therapy for maintaining normal thyroid
hormone levels, growth, and development may have
a predictive role for differentiating permanent forms
of CH from the transient forms. Diagnosing transient
hypothyroidism is important to avoid lifelong unnecessary
therapy. Further studies with larger sample sizes and longterm follow-up are needed to confirm the etiology and
determine the predictive factors to differentiate forms of
CH.
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